7 years ago

Arecor Secures £6 Million to Advance Diabetes Treatment Solutions

  • Arecor, a UK-based biopharmaceutical formulation company, has raised £6 million in funding led by Calculus Capital with participation from Albion Capital and Downing Ventures

  • The funds will be used to advance pharmaceutical drugs for diabetes and other conditions

  • Arecor's technology platform creates drugs that mimic the natural insulin response of healthy individuals, improving health outcomes for diabetes patients

  • The company plans to complete clinical trials for its diabetic compounds and partner for late-stage studies and global market access.

      • ProblemHealthcare

      "Making insulin delivery more effective and mimicking the natural response of a healthy person to glucose, improving health outcomes for people with diabetes."

      Solution

      "Developing ultra-rapid acting insulin and ultra-concentrated insulin that closely mimic the insulin profile of healthy individuals, improving health outcomes and quality of life for people living with diabetes."

      Covered on